Intensive Robotic Rehabilitation in Children With Hemiparesia Using GEOSYSTEM
NCT ID: NCT04246788
Last Updated: 2022-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2020-07-17
2021-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Exoskeletal Robot-Assisted Gait Training on Children With Cerebral Palsy: A Pilot Study
NCT05759182
The Effects of Upper Extremity Robotic Rehabilitation in Children With Spastic Hemiparetic Cerebral Palsy
NCT06352762
The Effects Of Upper Extremity Robotic Rehabilitation On Upper Extremity Functions And Gait Parameters
NCT05136612
Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy
NCT01700153
Intensive Rehabilitation Program for Upper Limb in Children and Adolescents With Cerebral Palsy
NCT07285837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective: To evaluate walking velocity with the GRAIL (gait real-time analysis and interactive lab) after intensive robot-assisted gait training using the G-EO system in hemiplegic children.
Secondary objectives :Other parameters that will be evaluate include:
* Endurance on the 6 minute walking test
* Joint angles and muscular contraction on the GRAIL
* Number of steps and travelled distance /24h, cardiac frequency and quality of sleep using actimeter bracelet
* Motor functions using the GMFM (Gross Motor Function Measure)
* Spasticity using the modified Ashworth scale
* The functional independence using the Functional Independence Measure (FIM™) for children,
* The quality of life using the Patient Global Impression (PGI-I)
* Muscular strength using the muscular testing cotation scale
* The musculo-squeletal and adipose composition using the peripherical quantitative computed tomography (pQCT)
* The cerebral area activation using functional MRI Study Type: Controlled randomized pilote study Number of centres: Monocentric study, University hospital of Clermont-Ferrand
Study procedure:
* Experimental group: 5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
* Control group : 3 sessions per week of 30 minutes of classical physiotherapy during two weeks
Study evaluation:
T0 : before rehabilitation :
* Actimeter for 24h
* 6 min walking test
* GRAIL
* Modified Ashworth scale
* FIM for children
* GMFM
* Muscular testing scale
* pQCT
* fMRI
T1 : one month after rehabilitation :
* idem T0
* PGI-I questionnary Principal judgement criteria: Walking velocity Secondary judgement criteria: endurance, joint angles, number of steps and travelled distance per 24h, quality of sleep, cardiac frequency, spasticity, functional independence, motor functions, muscular strength, musculo-squeletal and adipose composition, brain activated areas.
Number of subjects:
* 20 patients in the experimental group
* 20 patients in the control group All patients enrolled in the control group will benefit of the GEOsystem rehabilitation at the end of the protocole
Inclusion criteria:
Hemiplegic children aged from 4 to 18 years, with a GMFCS (Gross Motor Function Classification System) score between I and III with lower limb involvement. Children must walk alone with or without aid at least 10 meters, must have acquired sitting position, must be able to understand simple orders to follow the rehabilitation program.
Non inclusion criteria:
No lower limb involvement, spasticity = 4 on the modified Ashworth scale, severe cardiorespiratory disease forbidding the rehabilitation program, orthopedic surgery or botulinic toxin injections in the last 6 months before the beginning of the study.
Study calendar:
* Starting inclusions: March 2020
* Experimental procedure: March 2020 to March 2021
* Data analyses and synthesis: April 2021 to Dember 2021
Statistical analyses Statistical analysis will be performed using Stata 13 software (Stata-Corp, College Station, TX) by an experimented statistician (Bruno Pereira) working in the university hospital of Clermont-Ferrand. A type-I error set at α=0.05 will be considered. Monovariate and multivariate analyses considering age as a covariable will be performed.
Ethical considerations This study has already been presented at the local ethical committee and will be presented in July 2019 at the national " comité de protection des personnes ". Written informed consent from both parents will be collected at the inclusion. This study will be in agreement with the declaration of Helsinki and the current regulations of clinical trials. It will be declared on the internet site "clinicaltrials.gov".
Expected results :
Intensive robot-assisted gait training using the G-EO system may improve the walking abilities in children with infantile hemiplegia and consequently improve their independence and quality of life. Musculo-squeletal parameters and profile of cerebral activated areas involved in praxia may also be modified by this intensive rehabilitation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 : experimental group
5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
Intensive robotic rehabilitation
5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
Cohort 2 : controle group
3 sessions per week of 30 minutes of classical physiotherapy during two weeks
classical physiotherapy
3 sessions per week of 30 minutes of classical physiotherapy during two weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intensive robotic rehabilitation
5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
classical physiotherapy
3 sessions per week of 30 minutes of classical physiotherapy during two weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GMFCS (Gross Motor Function Classification System) score between I and III with lower limb involvement.
* Children must walk alone with or without aid at least 10 meters, must have acquired sitting position, must be able to understand simple orders to follow the rehabilitation program.
* Free and informed consent of holders of parental authority and of the patient
* Affiliated to the social security system
Exclusion Criteria
* spasticity = 4 on the modified Ashworth scale,
* severe cardiorespiratory disease forbidding the rehabilitation program,
* orthopedic surgery or botulinic toxin injections in the last 6 months before the beginning of the study.
4 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université d'Auvergne
OTHER
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Sarret
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont Ferrand
Clermont-Ferrand, Auvergne, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A02218-49
Identifier Type: OTHER
Identifier Source: secondary_id
RBHP 2019 SARRET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.